CN111166749A - Application of sanguinarine in inhibiting growth of streptococcus pneumoniae - Google Patents
Application of sanguinarine in inhibiting growth of streptococcus pneumoniae Download PDFInfo
- Publication number
- CN111166749A CN111166749A CN202010140380.4A CN202010140380A CN111166749A CN 111166749 A CN111166749 A CN 111166749A CN 202010140380 A CN202010140380 A CN 202010140380A CN 111166749 A CN111166749 A CN 111166749A
- Authority
- CN
- China
- Prior art keywords
- streptococcus pneumoniae
- sanguinarine
- application
- application according
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims abstract description 67
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims abstract description 67
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 229940084560 sanguinarine Drugs 0.000 title claims abstract description 38
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 title claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract 3
- 230000002147 killing effect Effects 0.000 claims abstract 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 229960001699 ofloxacin Drugs 0.000 claims description 8
- 239000004098 Tetracycline Substances 0.000 claims description 7
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 229960002180 tetracycline Drugs 0.000 claims description 7
- 229930101283 tetracycline Natural products 0.000 claims description 7
- 235000019364 tetracycline Nutrition 0.000 claims description 7
- 150000003522 tetracyclines Chemical class 0.000 claims description 7
- 206010059866 Drug resistance Diseases 0.000 claims description 6
- 238000003113 dilution method Methods 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims 3
- 229940047766 co-trimoxazole Drugs 0.000 claims 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 229960005404 sulfamethoxazole Drugs 0.000 description 4
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 229960003702 moxifloxacin Drugs 0.000 description 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002770 ertapenem Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960003376 levofloxacin Drugs 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241001233914 Chelidonium majus Species 0.000 description 1
- 241000531495 Corydalis edulis Species 0.000 description 1
- ZUAPXIXLBSQDNW-UHFFFAOYSA-N Dihydroavicine Natural products Cc1cc2OCOc2c3CNc4c(ccc5cc6OCOc6cc45)c13 ZUAPXIXLBSQDNW-UHFFFAOYSA-N 0.000 description 1
- 108010074303 Dihydrobenzophenanthridine oxidase Proteins 0.000 description 1
- VXPARNCTMSWSHF-DNVSUFBTSA-N Dihydrosanguinarine Natural products O=C1[C@H](C(C)=C)C[C@]2(CO)[C@@H](C)[C@H](O)CCC2=C1 VXPARNCTMSWSHF-DNVSUFBTSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 240000007849 Macleaya cordata Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010058859 Pneumococcal bacteraemia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
- 241001134656 Staphylococcus lugdunensis Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- LOAQRYJNIQZQQB-UHFFFAOYSA-N benzo[k]phenanthridine;isoquinoline Chemical class C1=NC=CC2=CC=CC=C21.C1=CC=CC2=C3C4=CC=CC=C4C=CC3=CN=C21 LOAQRYJNIQZQQB-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- CIUHLXZTZWTVFL-UHFFFAOYSA-N dihydrosanguinarine Chemical compound C1=C2OCOC2=CC2=C3N(C)CC4=C(OCO5)C5=CC=C4C3=CC=C21 CIUHLXZTZWTVFL-UHFFFAOYSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- YOWNVPAUWYHLQX-UHFFFAOYSA-N fluazuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C(OC=2C(=CC(=CN=2)C(F)(F)F)Cl)=C1 YOWNVPAUWYHLQX-UHFFFAOYSA-N 0.000 description 1
- 229950006719 fluazuron Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 229960003250 telithromycin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了血根碱在抑制肺炎链球菌生长中的应用，根据血根碱对肺炎链球菌具有较好的体外杀灭作用，能够抑制肺炎链球菌的生长，且最低杀菌浓度为31.2μg/mL，最小抑菌浓度为15.6μg/mL，本发明提出了血根碱对肺炎链球菌具有抑制作用，在医药等领域具有广泛的应用价值。The invention discloses the application of sanguinarine in inhibiting the growth of Streptococcus pneumoniae. According to the fact that sanguinarine has a good in vitro killing effect on Streptococcus pneumoniae, it can inhibit the growth of Streptococcus pneumoniae, and the minimum bactericidal concentration is 31.2 μg/ mL, and the minimum inhibitory concentration is 15.6 μg/mL. The invention proposes that sanguinarine has an inhibitory effect on Streptococcus pneumoniae, and has wide application value in medicine and other fields.
Description
Technical Field
The invention relates to the field of medicine and food safety, in particular to application of sanguinarine in inhibiting growth of streptococcus pneumoniae.
Background
Streptococcus pneumoniae (Streptococcus pneumoniae) is a gram-positive bacterium belonging to the genus Streptococcus of the family Streptococcus, and is the main pathogenic bacterium of children with community-acquired pneumonia, and Streptococcus pneumoniae infection is caused by invasion of Streptococcus pneumoniae in vivo, and the main symptoms include pneumonia, meningitis, otitis media and the like. Normally, streptococcus pneumoniae is often in a bacteria-carrying state and is mainly attached to epithelial cells of the nasopharynx part and oral cavity of a human body, but once the immune function of the body is reduced or the body is invaded by physiology, damaged by mechanical barriers and the like, more chances are provided for the reproduction of streptococcus pneumoniae, and the streptococcus pneumoniae can spread to nasal cavities, bronchus, middle ears, lungs and the like, so that inflammatory reaction of organs is caused, systemic infection is caused when the streptococcus pneumoniae is serious, and the life and health are seriously threatened. Studies have shown that streptococcus pneumoniae primarily causes lobar pneumonia in humans. 75% of adult pneumococcal pneumonia and more than 50% of severe pneumococcal bacteremia are caused by streptococcus pneumoniae types 1-8. Streptococcus pneumoniae types 6, 14, 19 and 23 often cause Streptococcus pneumoniae disease in children. 40-70% of normal persons carry virulent streptococcus pneumoniae in their upper respiratory tract. According to the age distribution of streptococcus pneumoniae infection reported in the literature, the infection accounts for 62% in the case of age less than two years, the disease season is mainly concentrated in winter, the disease rate is 56%, and the main disease is pneumonia. The sensitivity rate of streptococcus pneumoniae to the fluazuron, ertapenem, vancomycin and moxifloxacin is 100%, the drug resistance rate to erythromycin is 98%, but the increasingly rising drug resistance of streptococcus pneumoniae to antibiotics brings great influence on the treatment work of hospitals.
Sanguinarine is a kind of benzophenanthridine isoquinoline alkaloid, mainly exists in the whole herb of Chelidonium majus, the root tuber of corydalis edulis, the whole herb of Macleaya cordata and the overground part of herba Sambuci Chiensis, and is prepared by oxidizing dihydrosanguinarine with dihydrobenzophenanthridine oxidase. Clinical studies have shown that sanguinarine has bacteriostatic and bactericidal effects on most bacteria in the oral cavity and has interfering effects on bacterial adhesion to the newly formed pellicle. Sanguinarine has inhibitory effect on some fungi, such as Trichophyton mentagrophytes, Microsporum canis, Microsporum floccosum and Aspergillus fumigatus. Sanguinarine also has antioxidant and anti-inflammatory effects, and can be used for controlling schistosomiasis, and has anti-tumor effect. Sanguinarine has been reported to have therapeutic effects on pancreatic cancer. Experiments prove that the sanguinarine can obviously inhibit the growth and development of pancreatic cancer cells AsPC-l and BxPC-3 and the colony forming capability of the pancreatic cancer cells. Haseeeb Ahsan (2007) also proves that sanguinarine can achieve the purpose of inducing apoptosis of human pancreatic cancer cells AsPC-1 and BxPC-3 through regulating the Bcl-2 protein. Chinese patent CN110772518A discloses the application of sanguinarine in inhibiting the growth of Staphylococcus lugdunensis, but there is no literature report on the aspect of sanguinarine inhibiting the growth of highly pathogenic Streptococcus pneumoniae at present.
Disclosure of Invention
The invention aims at solving the problem of drug resistance in clinical medicine and food safety at present and aims at providing the application of sanguinarine in inhibiting the growth of streptococcus pneumoniae.
In order to achieve the purpose, the invention adopts the technical scheme that:
the resistance of streptococcus pneumoniae to antibiotics is determined by a micro-double dilution method, and then the Minimum Inhibitory Concentration (MIC) and the Minimum Bactericidal Concentration (MBC) of sanguinarine to streptococcus pneumoniae are determined. The results show that: sanguinarine has good antibacterial effect on Streptococcus pneumoniae, and can be used for inhibiting growth of Streptococcus pneumoniae.
Preferably, the streptococcus pneumoniae is human streptococcus pneumoniae of multiple antibiotics in ofloxacin, tetracycline and compound sulfamethoxazole.
Preferably, the streptococcus pneumoniae is selected from human streptococcus pneumoniae of ofloxacin, tetracycline and compound neonomine.
Preferably, the minimum bactericidal concentration of the sanguinarine is 31.2 mu g/mL, and the minimum inhibitory concentration is 15.6 mu g/mL.
The invention has the beneficial effects that:
the invention starts from the existing medicinal plant resource library, develops a potential drug-resistant bacteria inhibitor, finds that the non-antibiotic compound sanguinarine can effectively inhibit the growth of streptococcus pneumoniae based on the research on the action of the sanguinarine on the streptococcus pneumoniae, provides a new thought and source for the research, development and application of the streptococcus pneumoniae inhibitor, and has wide application value in the fields of medicines and the like.
Furthermore, the invention defines the inhibition effect of sanguinarine on streptococcus pneumoniae, and the sanguinarine is used as an antibiotic substitute, so that the problems of drug resistance and infection of streptococcus pneumoniae can be effectively relieved or solved, and the fatality rate is reduced.
Detailed Description
The present invention will be described in further detail with reference to examples. The examples are only for explaining the present invention and do not limit the scope of protection of the present invention.
1. Drug sensitivity test of streptococcus pneumoniae
The invention takes a plurality of humanized streptococcus pneumoniae (strain samples are taken from Haizi hospital in Beijing) as starting strains, and selects 10 common antibiotics such as levofloxacin, ofloxacin, moxifloxacin, erythromycin, chloramphenicol, telithromycin, tetracycline, vancomycin, linezolid and compound sulfamethoxazole for testing.
And (3) selecting and culturing the pure colonies for 18-24 hours, uniformly dissolving the pure colonies in 2-5 mL of sterile physiological saline, and adjusting the turbidity of the pure colonies to be equal to that of a 0.5 McLeod turbiditube. Antibiotics, bacterial liquid and TSB liquid culture medium are added into a 96-hole culture plate for overnight culture by using a test tube double dilution method, and liquid medicine groups with different concentrations are all three in parallel, so that the reliability of experimental data is ensured. And (3) measuring the minimum inhibitory concentration of sanguinarine to streptococcus pneumoniae by using a microplate reader. The bacteriostatic result is judged according to the national standard administration committee of the united states clinical laboratory (CLSl2017), the judgment standard is shown in table 1, and the experimental result is shown in table 2. From this, it was found that the 2# strain had high resistance (type 2 for the 1# strain and type 6 for the 2# strain).
TABLE 1 results of the national Committee for standardization management of the clinical laboratory (CLSl2017) standards
TABLE 2 MIC results of drug sensitivity test of human Streptococcus pneumoniae
2. Inhibition of multiple drug-resistant strains by sanguinarine
To take full account ofThe medicine is safe, the sanguinarine single active ingredient is taken as a research object, and a standard strain (ATCC-49619, sensitive to antibiotics such as amoxicillin, meropenem, ertapenem, levofloxacin, ofloxacin, moxifloxacin, erythromycin and the like) is taken as a reference for researching the inhibition effect. Selecting and culturing for 24 hr, dissolving the pure bacterial colony in 5mL TSB liquid culture medium, adjusting turbidity to 0.5 McLeod turbiditube, and measuring OD with enzyme labeling instrument600The value is obtained. The sanguinarine with the concentration of 1000 mug/mL is prepared by dimethyl sulfoxide and used as a liquid medicine, the liquid medicine, a bacterial liquid and a TSB liquid culture medium are added into a 96-hole culture plate for overnight culture by using a test tube double dilution method, and liquid medicine groups with different concentrations are all three in parallel, so that the reliability of experimental data is ensured.
The Minimal Inhibitory Concentration (MIC) of sanguinarine to streptococcus pneumoniae is measured by a microplate reader, a drug dilution gradient is added to a cultured bacterium solution by taking the MIC concentration as a reference, the corresponding culture solution is transferred to a sterile TSA solid culture medium to be cultured for 24 hours, if no single colony is generated, the corresponding concentration is the Minimal Bactericidal Concentration (MBC) of sanguinarine to streptococcus pneumoniae, and the experimental result is shown in table 3.
TABLE 3 inhibition of Streptococcus pneumoniae by sanguinarine
As shown in Table 3, sanguinarine has a good inhibitory effect on Streptococcus pneumoniae of ofloxacin, tetracycline and compound sulfamethoxazole, and the MIC and MBC of the sanguinarine and the compound sulfamethoxazole are respectively 15.6 mu g/mL and 31.2 mu g/mL respectively. The results show that sanguinarine has bacteriostatic effects not only on the streptococcus pneumoniae reference strain, but also on streptococcus pneumoniae of the present invention (e.g., strain # 2).
According to the experimental results, by combining the characteristics of wide sources of Chinese herbal medicines, less adverse reactions, difficult generation of drug resistance and the like, the active single-product component sanguinarine can be obtained to directly play an inhibiting role for clinically main streptococcus pneumoniae, so that the infection problem of the streptococcus pneumoniae can be effectively relieved or solved, the fatality rate is reduced, a scientific basis is provided for researching clinically separated bacteriostatic agents of the streptococcus pneumoniae, and a new thought and source are provided for developing drugs and antibiotic substitutes for inhibiting the streptococcus pneumoniae.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010140380.4A CN111166749A (en) | 2020-03-03 | 2020-03-03 | Application of sanguinarine in inhibiting growth of streptococcus pneumoniae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010140380.4A CN111166749A (en) | 2020-03-03 | 2020-03-03 | Application of sanguinarine in inhibiting growth of streptococcus pneumoniae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111166749A true CN111166749A (en) | 2020-05-19 |
Family
ID=70647246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010140380.4A Pending CN111166749A (en) | 2020-03-03 | 2020-03-03 | Application of sanguinarine in inhibiting growth of streptococcus pneumoniae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111166749A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996007329A1 (en) * | 1994-09-09 | 1996-03-14 | University Of Maryland | Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases |
| CN1364463A (en) * | 2002-01-28 | 2002-08-21 | 赵凤和 | Berberis poiretii schneid detoxicating and inflammation diminishing tablet and its preparing process |
| CN101129364A (en) * | 2007-08-29 | 2008-02-27 | 成都军区昆明总医院 | Use of protoberberine alkaloid in preparing against bacterial resistance medicament |
| WO2008146164A2 (en) * | 2007-05-25 | 2008-12-04 | Novartis Ag | Streptococcus pneumoniae pilus antigens |
| CN101347512A (en) * | 2008-09-05 | 2009-01-21 | 郑州后羿制药有限公司 | Macleaya cordata injection and preparation thereof |
-
2020
- 2020-03-03 CN CN202010140380.4A patent/CN111166749A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996007329A1 (en) * | 1994-09-09 | 1996-03-14 | University Of Maryland | Bacteriophage-encoded enzymes for the treatment and prevention of dental caries and periodontal diseases |
| CN1364463A (en) * | 2002-01-28 | 2002-08-21 | 赵凤和 | Berberis poiretii schneid detoxicating and inflammation diminishing tablet and its preparing process |
| WO2008146164A2 (en) * | 2007-05-25 | 2008-12-04 | Novartis Ag | Streptococcus pneumoniae pilus antigens |
| CN101129364A (en) * | 2007-08-29 | 2008-02-27 | 成都军区昆明总医院 | Use of protoberberine alkaloid in preparing against bacterial resistance medicament |
| CN101347512A (en) * | 2008-09-05 | 2009-01-21 | 郑州后羿制药有限公司 | Macleaya cordata injection and preparation thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张艳等: ""血水草的研究进展"", 《时珍国医国药》 * |
| 王桂琴、强华主编: "《医学微生物学》", 30 September 2016, 中国医药科技出版社 * |
| 陈玲，尹海鹰主编: "《内科护理学》", 31 July 2018, 江苏凤凰科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2826473B1 (en) | Antibacterial use of patchoulol | |
| JP2012531448A (en) | Composition containing berberine or an analogue thereof for treating skin diseases associated with rosacea or blush | |
| JP6839329B2 (en) | Composition for the management of Helicobacter pylori infection | |
| CN111939156B (en) | A kind of combined antibacterial drug composition and application thereof | |
| JP7225088B2 (en) | 9-aminomethylminocycline compounds and uses thereof | |
| CN110652512B (en) | Application of crizotinib in preparation of anti-gram-positive-bacteria drugs | |
| US20250121013A1 (en) | Use of bacillus amyloliquefaciens for preventing and treating parkinson's disease | |
| Luo et al. | Adverse reaction report and retrospective analysis of black hairy tongue caused by linezolid | |
| CN111166749A (en) | Application of sanguinarine in inhibiting growth of streptococcus pneumoniae | |
| Shrestha et al. | Antibiotic sensitivity pattern in culture positive typhoid fever cases isolated at Patan hospital | |
| KR20080064177A (en) | How to treat diarrhea associated with Clostridium difficile | |
| US20230404969A1 (en) | Compositions and method for effective management of peritonitis | |
| CN110772518A (en) | Application of sanguinarine in inhibiting the growth of Staphylococcus ludens | |
| CN111202735A (en) | Application of chelerythrine in inhibiting growth of streptococcus pneumoniae | |
| CN110946862B (en) | Application of sanguinarine in inhibiting the growth of multi-drug resistant Enterobacter | |
| CN116687929A (en) | Application of sanguinarine in preparing medicament for preventing and treating clinical rare fungus related infectious diseases | |
| CN110934859B (en) | Application of luteolin in inhibiting the growth of multi-drug-resistant Providencia reinhardtii | |
| CN119161298B (en) | Small molecule capable of inhibiting clostridium difficile infection | |
| CN117122595A (en) | Uses of pyridine derivatives | |
| CN111000845B (en) | Application of chelerythrine in inhibiting the growth of multidrug-resistant Providencia rettgeri | |
| CN114886902A (en) | Application of bardoxolone in preparation of antibacterial drugs | |
| Maslov et al. | The Application Arbutin in Elimination Resistance of Antibiotics Against Gramm-Negative Multi-Drug Resistance Bacteria of Acinetobacter baumanni and Klebsiella pneumoniae | |
| van de Wetering et al. | Supportive care in paediatric oncology | |
| US8415289B2 (en) | Bacterial-derived BLIS for treatment of acne | |
| CN110876749A (en) | Application of chelerythrine in inhibiting growth of multiple drug-resistant serratia marcescens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200519 |
|
| RJ01 | Rejection of invention patent application after publication |